Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) hit a new 52-week low during trading on Friday . The company traded as low as $9.00 and last traded at $9.19, with a volume of 261280 shares. The stock had previously closed at $9.22.
Astellas Pharma Price Performance
The company's 50 day moving average price is $9.63 and its 200 day moving average price is $10.22. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.80 and a current ratio of 1.04. The company has a market cap of $16.18 billion, a price-to-earnings ratio of -40.63 and a beta of 0.31.
Astellas Pharma (OTCMKTS:ALPMY - Get Free Report) last issued its quarterly earnings results on Tuesday, February 4th. The company reported $0.30 EPS for the quarter. Astellas Pharma had a positive return on equity of 13.69% and a negative net margin of 3.10%. On average, equities research analysts predict that Astellas Pharma Inc. will post 0.42 earnings per share for the current fiscal year.
About Astellas Pharma
(
Get Free Report)
Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.
See Also
Before you consider Astellas Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astellas Pharma wasn't on the list.
While Astellas Pharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
